Streamlining vaccine development and production with modality-specific purification tools for mRNA and beyond

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Streamlining vaccine development and production with modality-specific purification tools for mRNA and beyond

Many factors contributed to the impressive speed with which COVID-19 vaccines were created, produced, and deployed, including novel vaccine modalities and recent advancements in downstream purification tools. These advancements remain powerful in the continued search for vaccines against persistent infectious agents such as HIV and malaria.

This webinar will present improved purification tools developed for rapid candidate screening and intensified downstream processing of various vaccine modalities, including mRNA, viral vector vaccines, and virus-like particles (VLPs). Examples of each vaccine modality and the associated purification tools will be given, including case studies and performance data.

Attend this webinar to learn more about

The variety of vaccine modalities used in the COVID-19 response and potential strategies for future vaccine development
Easy vaccine candidate screening via C-tag technology and its advantages over His-Tag
How affinity chromatography resins can help to improve the purification process of new vaccine modalities such as mRNA- or protein-based vaccines or viral vectors
How ion exchange resins can be leveraged for purifying VLPs and viral vector vaccines

Eugene Sun

Field Application Scientist, Bioproduction Group at Thermo Fisher Scientific

Eugene Sun is the Field Application Scientist for the Northeast region of North America and is responsible for providing technical support for POROS and CaptureSelect chromatography resins. Prior to joining Thermo Fisher Scientific Bioproduction Group in 2021, Eugene supported Amgen's Pivotal Drug Substance Technologies group in Cambridge, Massachusetts and was responsible for the development, characterization, and scale-up support of downstream processes to enable commercial advancement of programs from clinical trials to marketing application. Prior to that, Eugene started his career supporting MedImmune/AstraZeneca's early drug discovery / pre-clinical pipeline down in Maryland as a member of the Purification Process Sciences department. Eugene has over 10 years of extensive bench-scale experience developing both early and late-stage purification processes across all downstream unit operations for monoclonal antibodies, various formats of bispecific antibodies such as Bispecific T-Cell engagers (BiTEs), and biosimilar programs. Eugene earned his Bachelor of Arts in Biochemistry and Music from Bowdoin College.